Many drug developers have examined new strategies for creating efficiencies in their development processes, including the adoption of genomics-based approaches. Genomic data can identify new drug targets for both common and rare diseases, can predict which patients are likely to respond to a specifi
Generating Evidence for Genomic Diagnostic Test Development: Workshop Summary
โ Scribed by Roundtable on Translating Genomic-Based Research for Health, theresa Wizemann, Institute of Medicine (Adam C. Berger)
- Publisher
- The National Academies Press
- Year
- 2011
- Tongue
- English
- Leaves
- 107
- Category
- Library
No coin nor oath required. For personal study only.
โฆ Synopsis
Ten years after the sequencing of the human genome, scientists have developed genetic tests that can predict a person's response to certain drugs, estimate the risk of developing Alzheimer's disease, and make other predictions based on known links between genes and diseases. However, genetic tests have yet to become a routine part of medical care, in part because there is not enough evidence to show they help improve patients' health.The Institute of Medicine (IOM) held a workshop to explore how researchers can gather better evidence more efficiently on the clinical utility of genetic tests. Generating Evidence for Genomic Diagnostic Test Development compares the evidence that is required for decisions regarding clearance, use, and reimbursement, to the evidence that is currently generated. The report also addresses innovative and efficient ways to generate high-quality evidence, as well as barriers to generating this evidence. Generating Evidence for Genomic Diagnostic Test Development contains information that will be of great value to regulators and policymakers, payers, health-care providers, researchers, funders, and evidence-based review groups.--Publisher's description.
โฆ Table of Contents
FrontMatter......Page 2
Reviewers......Page 12
Acknowledgments......Page 14
Contents......Page 16
Tables, Figures, and Boxes......Page 18
Abbreviations and Acronyms......Page 20
1 Introduction......Page 22
2 Stakeholder Perspectives on Evidence......Page 26
3 Approaches to Evidence Generation......Page 46
4 Overcoming Barriers for Evidence Generation......Page 64
5 Considerations Moving Forward......Page 74
6 Final Remarks......Page 80
References......Page 84
Appendix A: Workshop Agenda......Page 88
Appendix B: Speaker Biographical Sketches......Page 92
Appendix C: Registered Attendees......Page 102
๐ SIMILAR VOLUMES
"Genome-Based Diagnostics: Demonstrating Clinical Utility in Oncology" is the summary of a workshop convened in May 2012 by the Roundtable on Translating Genomic-Based Research for Health and the Center for Medical Technology Policy of the Institute of Medicine to foster the identified need for furt
Knowing one's genetic disposition to a variety of diseases, including common chronic diseases, can benefit both the individual and society at large. The IOM's Roundtable on Translating Genomic-Based Research for Health held a workshop on March 22, 2010, to bring together diverse perspectives on the
Genomics is the study of the entire human genome. Genomics explores not only the actions of single genes, but also the interactions of multiple genes with each other and with the environment. As a result, genomics has great potential for improving the health of the public. However, realizing the ben